Troxacitabine

曲沙他滨

Report date: 2022/12/07 17:52:29
NME

Base Information

Drug NameTroxacitabine
Drug Alias NametroxacitabinetroxacitabinatroxacitabinumTroxatylBCH-4556 +[8] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues
Mechanisms of ActionDNA inhibitors
TargetsDNA
Therapy Area/IndicationsSolid tumoursLeukemia, Myeloid, AcuteLeukemia +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShire
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesGuangxi Huibaoyuan Pharmaceutical Technology Co LtdBeijing Hebabiz Management Co Ltd
Inactive CompaniesShireSgx Pharmaceuticals Inc
Active IndicationsSolid tumours
Inactive IndicationsLeukemia, Myeloid, AcuteLeukemiaNeoplasms

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG